United States · Hospital & health care startup

DeepMetrics

DeepMetrics is an AI-driven company focused on automating intensive care unit (ICU) processes.

Funding reportedLast round: Seed

Hospital & health careNew York, United States

About DeepMetrics

DeepMetrics is an AI-driven company focused on automating intensive care unit (ICU) processes.

Founded in 2020 and based in New York, NY, the company specializes in machine learning solutions for mechanical ventilator control in hospitals. With a team of 11-50 employees, DeepMetrics leverages advanced algorithmic techniques and large-scale data to tackle challenges in digital healthcare. The company's primary offering is an AI model that automatically adjusts ventilator settings, enhancing ICU monitoring and management. This platform operates at a level comparable to an intensivist, providing mathematical guarantees of optimal performance. DeepMetrics has validated its AI model through extensive testing on around 2,000 ICU patients, demonstrating its effectiveness in critical care management.

What company datasets say DeepMetrics raised

Funding, as reported

Reported in all$1.5Bin dollars
Rounds1
Last roundSeed
Last round size$4.2M
Last round dateJul 2021
Investors listed4

Founders and team

From DeepMetrics's own website: 1 founder, 1 on the team.

Hyun Oh SongFounder & CEO
  • Seokjun LeeHead of engineering

On a portfolio page

Investors who name them

Each firm lists DeepMetrics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

The company, in detail

What they build

Known for

hospital & health carehospitals & health care

Built with from their website

Google WorkspaceGoogle MeetNginxGoogle Search ConsoleGmail

Sector
Hospital & health care
Industry code
NAICS 334510, 513210, SIC 3841, 7372
Region
New York
Full record
Every detail in the company directory

Hospital & health care in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put DeepMetrics in front of investors. Or tell us what we have wrong.